Viking Therapeutics (NASDAQ:VKTX), often touted as an attractive obesity play, shed more than a third of its value this week after mid-stage trial data for its oral obesity candidate VK2735 disappointed Wall Street.
On Tuesday, the San Diego, California-based biotech announced that